Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$29.88 USD

29.88
15,713,491

+0.05 (0.17%)

Updated Sep 18, 2024 02:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Pfizer's Trumenba Vaccine Approved by European Commission

Pfizer Inc. (PFE) announced that its Trumenba vaccine received approval from the European Commission (EC) for active immunization of people aged 10 years and older for the prevention of invasive disease caused by Neisseria meningitidis serogroup B (MenB).

    Pfizer's Epogen Biosimilar Gets Positive FDA Committee Vote

    Pfizer, Inc. (PFE) announced that an FDA advisory committee has recommended approval of its biosimilar version of ESA Epogen and Procrit.

      Celldex's Immuno-Oncology Pipeline Continues to Impress

      On May 25, we issued an updated research report on Hampton, NJ-based Celldex Therapeutics, Inc. (CLDX).

        Arpita Dutt headshot

        Pharma Stock Roundup: Label Expansion for Merck Drug, Aerie Up On Eye Data

        Merck (MRK) got another approval for Keytruda while Aerie shot up on positive data.

          Aerie's Ophthalmic Candidate Positive in Registration Trial

          Aerie Pharmaceuticals, Inc. (AERI) announced positive primary efficacy results of the 90-day phase III registration trial -- Mercury 2 -- for its pipeline candidate Roclatan.

            Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis

            Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has approved their pipeline candidate sarilumab to be marketed under the trade name of Kevzara.

              Shire (SHPG) Up on Positive Phase III Study Data on HAE Drug

              Shire plc (SHPG) announced positive top-line results from the phase III study, HELP, on HAE candidate, lanadelumab.

                Merck's (MRK) Keytruda Gets FDA Nod for Two New Indications

                Merck & Co., Inc. (MRK) announced that the FDA has approved two new indications for Keytruda (pembrolizumab), the company's anti-PD-1 therapy.

                  Merck KGaA (MKGAF) Q1 Earnings Fall Y/Y, Revenues Increase

                  Merck KGaA (MKGAF) reported first-quarter 2017 earnings of $1.28 per American Depositary Share, 14.7% lower than the year-ago figure of $1.50.

                    Endocyte (ECYT) Focused on Two Lead Pipeline Candidates

                    We issued an updated report on Endocyte, Inc. (ECYT) on May 17.

                      J&J (JNJ) Plans to Seek Approval for 10 New Drugs by 2021

                      Johnson & Johnson, Inc. (JNJ) discussed its future plans and showcased a strong pipeline of transformational medicines at a meeting held yesterday with industry analysts.

                        The Zacks Analyst Blog Highlights: Pfizer, Home Depot, ConocoPhillips, Prudential Financial and Canadian Pacific

                        The Zacks Analyst Blog Highlights: Pfizer, Home Depot, ConocoPhillips, Prudential Financial and Canadian Pacific

                          Sangamo's (SGMO) Hemophilia A Drug Gets Fast-Track Status

                          Sangamo Therapeutics, Inc. (SGMO) announced that the FDA has granted fast track designation to pipeline candidate, SB-525.

                            5 Reasons Why Merck (MRK) is a Good Stock to Buy Now

                            It looks like a great stock to buy now.

                              Sheraz Mian headshot

                              Stock Market Today & Home Depot, Pfizer and ConocoPhillips Research Reports

                              Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Home Depot (HD) and ConocoPhillips (COP).

                                Aerie's (AERI) Rhopressa NDA Sufficient for FDA Review

                                Aerie Pharmaceuticals, Inc. (AERI) announced that it has received notification from the FDA about the completion of the initial 60-day review of the NDA for Rhopressa

                                  What's in Store for Merck KGaA (MKGAF) in Q1 Earnings?

                                  Merck KGaA (MKGAF) is scheduled to report first-quarter 2017 earnings results on May 18.

                                    Arpita Dutt headshot

                                    Pharma Stock Roundup: Mylan, Teva Q1 Earnings, Roche Drug Misses in Pivotal Study

                                    While companies like Mylan (MYL), Allergan and Teva reported Q1 results this week, several companies provided updates on their cancer drugs.

                                      Model N (MODN) Q2 Loss Narrower than Expected, Guides Well

                                      Model N, Inc. (MODN) reported second-quarter 2017 adjusted loss of 25 cents per share, which was wider than the year-ago quarter's loss of 21 cents.

                                        Arpita Dutt headshot

                                        Pharma Stock Roundup: Merck, Pfizer Report Q1 Earnings, J&J Talc Powder Lawsuit

                                        Major pharma companies like Pfizer (PFE) and Merck reported Q1 results last week.

                                          Swarup Gupta headshot

                                          Dow 30 Stock Roundup: Apple, Merck Beat; Pfizer Misses on Revenues

                                          The Dow traded inside a tight band during a week marked by key earnings releases and legislative developments.

                                            Merck vs. Pfizer: Which Stock Looks Better Post-Earnings?

                                            Pfizer is better positioned than Merck and thus calls for investors' attention post earnings.

                                              Aerie (AERI) Posts Wider-Than-Expected Q1 Loss, Expenses Up

                                              Aerie Pharmaceuticals, Inc. (AERI) posted first-quarter 2017 loss of 76 cents per share (including stock-based compensation), wider than the Zacks Consensus Estimate of a loss of 74 cents.

                                                Momenta (MNTA) Q1 Loss Narrower than Expected, Sales Beat

                                                Momenta Pharmaceuticals Inc. (MNTA) reported loss of 46 cents per share in the first quarter of 2017,which was narrower than the Zacks Consensus Estimate loss of $1.09. In fact, the company posted a loss of 35 cents in the year-ago quarter as well.

                                                  Drug Stock Q1 Earnings Releases on May 4: ZTS, REGN & More

                                                  Here we have four pharma companies that are set to report first-quarter results on May 4. Let's see how things are shaping up for them.